Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Receives Average Rating of “Buy” from Analysts

Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) have earned an average recommendation of “Buy” from the five brokerages that are presently covering the stock, MarketBeat reports. Five research analysts have rated the stock with a buy recommendation. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $33.60.

A number of equities analysts have recently issued reports on the company. Wedbush increased their price target on Kiniksa Pharmaceuticals from $30.00 to $34.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 23rd. Jefferies Financial Group began coverage on shares of Kiniksa Pharmaceuticals in a report on Friday, September 13th. They set a “buy” rating and a $40.00 target price on the stock.

Kiniksa Pharmaceuticals Price Performance

Shares of KNSA opened at $26.25 on Friday. The firm has a market capitalization of $1.86 billion, a price-to-earnings ratio of 238.64 and a beta of 0.33. Kiniksa Pharmaceuticals has a 1-year low of $14.12 and a 1-year high of $27.92. The company has a 50-day moving average of $25.02 and a 200 day moving average of $21.17.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last posted its quarterly earnings results on Tuesday, July 23rd. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.09) by $0.03. Kiniksa Pharmaceuticals had a negative net margin of 3.10% and a negative return on equity of 7.79%. The firm had revenue of $108.30 million during the quarter, compared to the consensus estimate of $90.60 million. During the same quarter in the previous year, the firm posted ($0.02) earnings per share. The company’s revenue was up 51.5% on a year-over-year basis. On average, equities analysts anticipate that Kiniksa Pharmaceuticals will post -0.31 earnings per share for the current fiscal year.

Insider Activity at Kiniksa Pharmaceuticals

In other Kiniksa Pharmaceuticals news, COO Eben Tessari sold 17,500 shares of the business’s stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $26.91, for a total value of $470,925.00. Following the completion of the transaction, the chief operating officer now directly owns 119,911 shares in the company, valued at $3,226,805.01. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, COO Eben Tessari sold 17,500 shares of Kiniksa Pharmaceuticals stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $26.91, for a total value of $470,925.00. Following the transaction, the chief operating officer now owns 119,911 shares of the company’s stock, valued at approximately $3,226,805.01. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider John F. Paolini sold 22,000 shares of the stock in a transaction that occurred on Tuesday, July 23rd. The shares were sold at an average price of $26.32, for a total transaction of $579,040.00. Following the sale, the insider now directly owns 47,803 shares of the company’s stock, valued at approximately $1,258,174.96. The disclosure for this sale can be found here. Insiders have sold a total of 260,564 shares of company stock valued at $6,727,929 over the last quarter. 54.57% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Hhlr Advisors LTD. purchased a new stake in shares of Kiniksa Pharmaceuticals during the first quarter worth about $61,868,000. Vanguard Group Inc. grew its position in Kiniksa Pharmaceuticals by 0.6% during the 1st quarter. Vanguard Group Inc. now owns 2,981,894 shares of the company’s stock worth $58,833,000 after purchasing an additional 16,595 shares during the last quarter. Rubric Capital Management LP increased its stake in Kiniksa Pharmaceuticals by 10.2% during the 2nd quarter. Rubric Capital Management LP now owns 2,419,103 shares of the company’s stock valued at $45,165,000 after purchasing an additional 223,094 shares in the last quarter. Granahan Investment Management LLC raised its holdings in shares of Kiniksa Pharmaceuticals by 35.2% in the fourth quarter. Granahan Investment Management LLC now owns 722,388 shares of the company’s stock worth $12,671,000 after buying an additional 188,174 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its stake in shares of Kiniksa Pharmaceuticals by 31.2% during the second quarter. Dimensional Fund Advisors LP now owns 664,040 shares of the company’s stock worth $12,398,000 after buying an additional 157,741 shares during the period. 53.95% of the stock is currently owned by hedge funds and other institutional investors.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.